PEPG 8-K SEC Filing Analysis

Latest settled — T+5d

PEPG ▼ -22.47% at T+5d

NEUTRAL call ✗ call lost -22.47% · α vs SPY -21.31% · entry $1.78 → $1.38

Next anchor: T+20d in 8h

Currently $1.38 · -22.47% from $1.78 entry

Entry anchored
May 12, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α +0.00%

$1.78

settled 28d ago

T+5d

-22.47%

call -22.47% · α -21.31%

$1.38

settled 22d ago

T+20d

—

call — · α —

—

in 8h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

PepGen reported Q1 2026 net loss of $17.8M ($-0.26/share), narrower than the $30.2M loss in Q1 2025, with cash of $132.3M sufficient into 2H 2027. The FREEDOM2-DM1 5 mg/kg cohort showed favorable safety and efficacy data, the 10 mg/kg cohort is fully enrolled with data expected in 2H 2026, but an FDA partial clinical hold remains unresolved.

Actionable Insight

The stock will trade on FREEDOM2 10 mg/kg data in 2H 2026 and resolution of the FDA partial clinical hold. Near-term catalyst is limited — monitor for FDA feedback and any preclinical study updates. The improved cash position reduces near-term dilution risk.

Key Facts

Net loss of $17.8M ($-0.26/share) for Q1 2026 vs $30.2M ($-0.92/share) in Q1 2025
Cash, cash equivalents and marketable securities of $132.3M as of March 31, 2026
FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data
FREEDOM2 10 mg/kg cohort fully enrolled, data on track for 2H 2026
FDA partial clinical hold on FREEDOM2 study remains unresolved
13 patients enrolled in open label extension at 5 mg/kg with no discontinuations

Financial Impact

Net loss improved by $12.4M YoY to $17.8M; cash burn of $16.2M in Q1 2026

net losscash positionR&D expenses

Risk Factors

FDA partial clinical hold could delay or derail FREEDOM2 trial if not resolved
10 mg/kg cohort data may not replicate 5 mg/kg safety/efficacy profile
Pre-revenue biotech with no approved products — binary clinical risk
Cash runway only into 2H 2027 — potential future dilution

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

85% bullish (13 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-219424
Document: pepg-20260512.htm	0001193125-26-219424
Document: 0001193125-26-219424-index-headers.html	0001193125-26-219424
Document: 0001193125-26-219424-index.html	0001193125-26-219424
Document: 0001193125-26-219424.txt	0001193125-26-219424
8-K Data (Synthetic)	0001193125-26-219424

5 reports for PEPG

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PEPG — sortable, filterable
	Type				Now
May 22, 2026 18d ago	EFFECT BEARISH ★ 7/10	$1.51 $1.47	▲ +2.65%	▲ +4.31%	$1.38 (+8.61%)
May 19, 2026 21d ago	S-3 BEARISH ★ 7/10	$1.38 $1.52	▼ −10.14%	▼ −7.90%	$1.38 (+0.00%)
May 12, 2026 28d ago	8-K NEUTRAL ★ 5/10	$1.78 $1.38	▼ −22.47%	▼ −21.31%	$1.38 (−22.47%)
Mar 4, 2026 13w ago	8-K MIXED ★ 6/10	$5.51 $6.15	▲ +11.72%	▲ +13.95%	$1.38 (−74.93%)
Mar 4, 2026 14w ago	Insider Cluster NEUTRAL ★ 3/10	$6.76 $6.29	▼ −6.95%	▼ −5.62%	$1.38 (−79.59%)

US Market Status

Market Closed — Opens Thu (9h 48m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access